Novavax, Inc. this week announced it has completed purification of a virus-like particle (VLP) vaccine candidate for the emerging H7N9 influenza and has initiated animal immunogenicity and efficacy studies.
The company began work on the strain in early April. Analysis and optimization of the gene sequences for the key viral hemagglutinin (HA) and Continue reading


